Biotech Values

[Whalatane]

PRTO. Hi Poorgrad . I'd appreciate you opinion on the following ...Feb 2019

https://www.jvascsurg.org/article/S0741-5214(18)31337-5/pdf

note in the discussion
Whereas vonapanitase did not meet its primary end point, there were several clinically meaningful indicators that vonapanitase may be an effective therapy in fistula creation.
Importantly, vonapanitase was associated with increases in secondary patency and use of the fistula for hemodialysis.

In your PRTO post you asked what's different about the final P 3 trial
From my read
1) doubled size of enrollment for the final P3 trial
2) secondary / tertiary endpts of previous trial are now co primary endpts on this final trial .

Would appreciate it if you could read the linked article and offer your opinion.
You were right about the earlier trials failing .......just wondering how you feel about this final one.

Data in March 2019

Wife is a PA in Renal ...writes reports on over 100 dialysis patients each month.
Time to fistula abandonment ( average of 3 yrs for her patients ) and risk of new fistulas never " maturing " well enough to be used for dialysis .....are major concerns for her patients and staff.

Kiwi